Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.2552W HIGH $10.42
Volume
40.89 K
Value Traded
1.22 M
Short % Float
17.95%
-0.97%Week
+23.67%1 Month
+6.26%3 Month
+36.06%6 Month
-19.59%5 Year
-82.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
440.57 M
EPS (TTM)
-0.70
P/E Ratio
-
Ent. Value
397.07 M
Total Shares
53.94 M
Float Shares
30.56 M
Insiders
43.33%
Institutions
18.43%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
DMAC Catalyst Timeline
Dated clinical, regulatory and corporate events for DiaMedica Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for DiaMedica Therapeutics Inc.
122Total events
7Upcoming
16Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Topline ReadoutDM199Clinical Data
Topline results from first FGR cohort to be presented in September
Early-Onset Fetal Growth Restrictionsource ↗
●R&D DayDM199Presentation
Key opinion leader call in September to discuss DM199 FGR potential
Early-Onset Fetal Growth Restrictionsource ↗
▲Enrollment CompleteDM199Trial
Enrollment completed in first of three planned FGR cohorts (6 participants, 5 µg/kg)
fetal growth restrictionsource ↗
▲First Patient DosedDM199Trial
Dosing begun in second FGR cohort at 10 µg/kg dose level
fetal growth restrictionsource ↗
●R&D DayPresentation
Conference call to provide business update and discuss Q2 2026 financial results
▲Enrollment CompleteDM199Trial
Enrollment complete in first cohort of Phase 2 FGR trial (6 participants, 5 µg/kg)
Early-Onset Fetal Growth Restrictionsource ↗
▲Enrollment UpdateDM199Trial
ReMEDy2 enrollment surpassed 85% of 200 participants needed for interim analysis
Acute Ischemic Strokesource ↗
▲Trial Authorization (CTA / IND)DM199Ex-US Regulatory
Health Canada authorized global Phase 2 early-onset preeclampsia study
Early-Onset Preeclampsiasource ↗
▲First Patient DosedDM199Trial
First patients dosed in Phase 2 trial of DM199 for Fetal Growth Restriction
Fetal Growth Restrictionsource ↗
◆FDA Feedback ReceivedDM199FDA Meeting
FDA feedback on DM199 preeclampsia nonclinical program
preeclampsiasource ↗
◆Oral PresentationPresentation
Corporate Presentation at Jefferies Global Healthcare Conference 2026
▲Topline ReadoutDM199Clinical Data
Positive topline results from Phase 2 late-onset preeclampsia Part 1a dose-extension cohort
Late-Onset Preeclampsiasource ↗
▲Primary Endpoint MetDM199Clinical Data
DM199 met primary endpoint with statistically significant SBP/DBP reductions in late-onset PE
Late-Onset Preeclampsiasource ↗
●FDA Feedback ReceivedDM199FDA Meeting
FDA written feedback received on nonclinical reproductive toxicity for US IND pathway
Preeclampsiasource ↗
●Trial InitiationDM199Trial
Enrollment commenced in Phase 2 investigator-sponsored FGR trial
fetal growth restrictionsource ↗
●Enrollment UpdateDM199Trial
Enrollment commenced in Phase 2 early-onset FGR trial
fetal growth restrictionsource ↗
▲Enrollment MilestoneDM199Trial
75% enrollment milestone in ReMEDy2 Phase 2/3 acute ischemic stroke trial
acute ischemic strokesource ↗
◆Oral PresentationPresentation
DiaMedica to participate in RBC Capital Markets Global Healthcare Conference fireside chat
●Quarterly UpdateCorporate
Conference call to discuss Q1 2026 financial results and business update
◆Oral PresentationPresentation
Leerink Partners Global Healthcare Conference Company Presentation
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
▲IND ClearanceDM199IND
Health Canada clearance to initiate Phase 2 study of DM199 in early-onset preeclampsia
early-onset preeclampsiasource ↗
◆Trial CompletionDM199Trial
REMEDY trial expected to complete in Q4 2019 or Q1 2020
Acute Ischemic Strokesource ↗
●Oral PresentationPresentation
DiaMedica management to present at 2019 Dougherty & Co. Institutional Investor Conference
▲Enrollment CompleteDM199Trial
Enrollment completed in Phase Ib CKD study
Chronic Kidney Diseasesource ↗
●IND SubmissionDM199IND
Protocol submitted to FDA for Phase II CKD study
Chronic Kidney Diseasesource ↗
▲Enrollment UpdateDM199Trial
REMEDY trial enrollment past two-thirds mark
Acute Ischemic Strokesource ↗
▲Partnership / LicenseDM199Corporate
Terminated license agreement with Ahon Pharma for DM199 in China; regained worldwide rights
Acute Ischemic Strokesource ↗
◆Trial InitiationDM199Trial
Phase 2 trial initiation in CKD expected in second half of 2019
chronic kidney diseasesource ↗
◆Oral PresentationDM199Presentation
Conference call and webcast to present interim Phase 1b results and proposed Phase 2 trial design
chronic kidney diseasesource ↗
▲Interim AnalysisDM199Trial
Interim results from Phase 1b trial of DM199 in CKD participants
chronic kidney diseasesource ↗
◆Trial CompletionDM199Trial
Completion of Phase Ib study of DM199 in CKD
Chronic Kidney Diseasesource ↗
◆Topline ReadoutDM199Clinical Data
Top-line results expected in June 2019
Chronic Kidney Diseasesource ↗
◆R&D DayPresentation
DiaMedica to present at 16th Annual Craig-Hallum Institutional Investor Conference
◆Oral PresentationDM199Presentation
CKD New Therapeutic Development: DM199 for Chronic Kidney Disease presentation at CKD3 summit
chronic kidney diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How DMAC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | DM199 | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C44 / 100
Pipeline Score
$129M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.3x
rNPV / MCap
Top 29%
Micro Cap(rank 192 of 658)
Percentile Rank
DiaMedica Therapeutics Inc. carries a moderate pipeline score (44/100), with $538M risk-adjusted pipeline value, led by DM199 in Acute Ischemic Stroke (Phase 2), across $184B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM199 Small moleculeCompletedNCT04123613 | Kidney Diseases | Phase 2 | COMPLETED | 79 | Mar 16, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every DMAC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DM199 | fetal growth restriction | Phase 2 | 2026-09-30 | six participants treated at the 5 µg/kg dose levelRead More | DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| STAHLBERG JAN10% Owner | Buy | 73,099 8,825,742 held | $8.57 | 11/25/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in DMAC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.1 % | 553.00 K | 221.25 K | 5.82% ( 12.17 K) |
DMAC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DMAC ranks across every disease it competes in
Competitive Position is a premium feature
See how DMAC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDMAC News
DMACDiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
DiaMedica Therapeutics has announced a virtual key opinion leader event scheduled for October 23, 2026, to discuss DM199 as a potential treatment for fetal growth restriction (FGR). The webinar will highlight preliminary Phase 2 results, emphasizing the therapeutic rationale for DM199. This event aims to engage experts in the field and share insights on FGR.
Read more →DMACDiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
DiaMedica Therapeutics Inc. will participate in four investor conferences in New York, including the Citi Biopharma Back to School Summit and the Cantor Global Healthcare Conference. The company's management, including CEO Rick Pauls, will engage with investors to discuss their clinical-stage biopharmaceutical developments. This participation highlights DiaMedica's commitment to advancing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Read more →DMACDiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
DiaMedica Therapeutics Inc. has announced its financial results for the second quarter of 2026, highlighting its ongoing commitment to developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. The company will hold a conference call to discuss these results and provide further business updates. This proactive communication indicates a focus on transparency and stakeholder engagement.
Read more →DMACDiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
DiaMedica Therapeutics Inc. will release its second quarter 2026 financial results on August 10th, after market close. The company is focused on innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. A live conference call is scheduled for August 11th to discuss the results and provide a business update.
Read more →DMACDiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DiaMedica Therapeutics Inc. announced the grant of stock options totaling 160,000 shares to a newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4). This move is part of the company's strategy to attract talent as it continues to focus on developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Read more →DMAC▲ +6.6%on this news
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
DiaMedica Therapeutics has announced the dosing of the first patients in a Phase 2 trial for DM199, aimed at treating fetal growth restriction. This marks a significant step in their clinical development process. Further details regarding the trial's objectives and expected outcomes were not provided.
Read more →DMACDiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
DiaMedica has received feedback from the FDA regarding its nonclinical program for DM199, which is aimed at addressing preeclampsia. The details of the feedback and its implications for the program have not been disclosed. This interaction with the FDA is a crucial step in the development process for DM199.
Read more →DMACDiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
DiaMedica Therapeutics is scheduled to present at the Jefferies Global Healthcare Conference in 2026. The event is expected to provide insights into the company's developments and future plans. Further details about the presentation and topics to be discussed have not been disclosed.
Read more →DMACDiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics has announced that it has achieved a 75% enrollment milestone in its ReMEDy2 Phase 2/3 trial for acute ischemic stroke. This progress indicates a strong commitment to advancing the study, which aims to evaluate the safety and efficacy of its treatment. The milestone is a crucial step towards completing the trial and potentially bringing new options to patients.
Read more →DMACDiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
DiaMedica Therapeutics is set to participate in the 2026 RBC Capital Markets Global Healthcare Conference. This event highlights the company's ongoing engagement with investors and stakeholders in the healthcare sector. Further details about their participation or agenda have not been disclosed.
Read more →DMACDiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
DiaMedica Therapeutics has released its financial results for the first quarter of 2026, along with key business highlights. However, the article does not provide specific details regarding the financial performance or business developments. The lack of substantial information limits the analysis of the company's current status.
Read more →DMACDiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
DiaMedica Therapeutics Inc. will release its first quarter 2026 financial results on May 6, 2026. A live conference call is scheduled for May 7, 2026, at 8:00 AM EDT to discuss these results and provide a business update. The company focuses on innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Read more →DMACDiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
DiaMedica Therapeutics has reported its financial results for the full year 2025, along with key business highlights. The details of the financial performance and strategic initiatives were discussed, although specific figures and outcomes were not provided in the article. The report aims to inform stakeholders about the company's current status and future direction.
Read more →DMAC▲ +7.8%on this news
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
DiaMedica Therapeutics Inc. will release its full-year 2025 financial results on March 30, 2026, after market close. The company will also host a conference call on March 31, 2026, at 7:00 AM CT to provide a business update. This event highlights DiaMedica's ongoing commitment to transparency and investor relations.
Read more →DMACDiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
DiaMedica Therapeutics has received Health Canada clearance to initiate a Phase 2 study of DM199 for early-onset preeclampsia. The trial, set to begin in 2026, will evaluate the safety and efficacy of DM199 in pregnant women. This regulatory approval follows promising results from an earlier trial in South Africa, highlighting the need for new treatments in this area.
Read more →DMACDiaMedica Therapeutics to Participate in Upcoming March 2026 Investor Conferences
DiaMedica Therapeutics Inc. will participate in three investor conferences in March 2026. CEO Rick Pauls and Chief Medical Officer Julie Krop will engage in discussions at the TD Cowen Healthcare Conference and Barclays Global Healthcare Conference, while Pauls will also present at the Leerink Partners Global Healthcare Conference. The company focuses on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
Read more →DMACDiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
DiaMedica Therapeutics Inc. will participate in three upcoming investor conferences, showcasing their commitment to engaging with the investment community. CEO Rick Pauls and Chief Medical Officer Julie Krop will lead discussions on their innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. These events are scheduled for March 2026 in Boston and Miami.
Read more →DMACDiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
DiaMedica Therapeutics Inc. announced the granting of stock options to a newly hired non-executive employee as an inducement for accepting employment. This grant, totaling 50,000 shares, complies with Nasdaq Listing Rule 5635(c)(4) and is part of the company's compensation strategy. The options have a ten-year term and will vest over time, contingent on the employee's continued service.
Read more →DMACDiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
DiaMedica Therapeutics Inc. will participate in the Lake Street Capital Markets 3rd Annual Best Ideas Growth Conference on September 12, 2019. CEO Rick Pauls will engage in one-on-one meetings with investors throughout the day. The conference aims to connect institutional investors with dynamic public growth companies.
Read more →DMACDiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
DiaMedica Therapeutics Inc. will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis. CEO Rick Pauls will host one-on-one meetings with institutional investors. The company is focused on developing treatments for chronic kidney diseases and neurological disorders, with ongoing studies in acute ischemic stroke and chronic kidney disease.
Read more →About DiaMedica Therapeutics Inc.
Headquarters301 CARLSON PARKWAY, MINNEAPOLIS, MN, 55305
BIOPHARMAWATCH ELITE PLUS
Trade the next DMAC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime